Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-17T17:50:09.159Z Has data issue: false hasContentIssue false

Neuroleptics, Lithium and Renal Function

Published online by Cambridge University Press:  29 January 2018

Derek G. Waller*
Affiliation:
University of Southampton, Southampton General Hospital, Southampton, SO9 4XY
J. Guy Edwards
Affiliation:
Department of Psychiatry, Royal South Hants Hospital, Southampton, SO9 4PE
A. Polak
Affiliation:
University of Southampton, St. Mary's Hospital, Portsmouth, PO3 6AD
*
∗ Correspondence.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Renal function test results in 26 patients on neuroleptic treatment, who had never received lithium or antidepressants, were compared with those in a matched group, treated with lithium; also, their tubular response to DDAVP was compared with that of 25 control subjects. Measurements of serum creatinine, creatinine clearance, and urinary albumin excretion showed no abnormality attributable to either neuroleptics or lithium. The maximum urine concentrating ability after DDAVP was significantly lower in the neuroleptic group than in controls, but significantly higher than in the lithium-treated patients. There was a significant correlation between excretion of urinary ß2-microglobulin and duration of neuroleptic treatment, but mean excretion rates were the same in both treatment groups. The results suggest that neuroleptics as well as lithium impair urine concentrating ability.

Information

Type
Research Article
Copyright
Copyright © 1985 The Royal College of Psychiatrists 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.